Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions
Гипофизарный полипептид, активирующий аденилатциклазу, и его рецепторы: от структуры к функциям
2000-06-01
SCID: 54.1/dqwmsy3x
Discuss with AI
PAC1 receptorPACAPPACAP receptorsVPAC1 and VPAC2 receptorsadenylyl cyclase
Figures from the paper
Abstract (AI)
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 38-amino acid peptide that was first isolated from ovine hypothalamic extracts on the basis of its ability to stimulate cAMP formation in anterior pituitary cells. PACAP belongs to the vasoactive intestinal polypeptide (VIP)-glucagon-growth hormone releasing factor-secretin superfamily. The sequence of PACAP has been remarkably well conserved during the evolution from protochordate to mammals, suggesting that PACAP is involved in the regulation of important biological functions. PACAP is widely distributed in the brain and peripheral organs, notably in the endocrine pancreas, gonads, and respiratory and urogenital tracts. Characterization of the PACAP precursor has revealed the existence of a PACAP-related peptide whose activity remains unknown. Two types of PACAP binding sites have been characterized. Type I binding sites exhibit a high affinity for PACAP and a much lower affinity for VIP whereas type II binding sites have similar affinity for PACAP and VIP. Molecular cloning of PACAP receptors has shown the existence of three distinct receptor subtypes, the PACAP-specific PAC1 receptor, which is coupled to several transduction systems, and the two PACAP/VIP-indifferent VPAC1 and VPAC2 receptors, which are primarily coupled to adenylyl cyclase. PAC1 receptors are particularly abundant in the brain and pituitary and adrenal glands whereas VPAC receptors are expressed mainly in the lung, liver, and testis. The wide distribution of PACAP and PACAP receptors has led to an explosion of studies aimed at determining the pharmacological effects and biological functions of the peptide. This report reviews the current knowledge concerning the multiple actions of PACAP in the central nervous system and in various peripheral organs including the endocrine glands, the airways, and the cardiovascular and immune systems, as well as the different effects of PACAP on a number of tumor cell types.
Key Findings
1
PACAP and its receptors are implicated in multiple functions across the central nervous system, endocrine, respiratory, cardiovascular, and immune systems, and affect diverse tumor cell types.
2
PACAP is a highly conserved 38-amino-acid peptide, suggesting an evolutionarily important role in regulating diverse biological functions.
3
PACAP is widely distributed throughout the brain and peripheral organs, including endocrine pancreas, gonads, and respiratory and urogenital tracts.
4
Three receptor subtypes have been identified: PAC1 is PACAP-specific and activates multiple signaling systems, while VPAC1 and VPAC2 respond to both PACAP and VIP and primarily stimulate adenylyl cyclase.
5
Two PACAP binding-site classes differ in ligand selectivity: type I sites preferentially bind PACAP, whereas type II sites bind PACAP and VIP with similar affinity.
Research Object
PACAP (pituitary adenylate cyclase-activating polypeptide) and its receptors in the central nervous system and peripheral organs
Research Subject
The molecular structure, receptor subtypes, distribution, signaling, and biological and pharmacological functions of PACAP
Publication Details
Publication Date
2000-06-01
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest